Day: March 14, 2022

REMINDER – Conference Call Notice: Intertape Polymer Group Inc. Fourth Quarter 2021 and Annual Results

Written by Customer Service on March 14, 2022. Posted in Public Companies.

MONTREAL and SARASOTA, Fla., March 14, 2022 (GLOBE NEWSWIRE) —DATE: Tuesday, March 15 2022 TIME: 10:00 A.M. (Eastern Time) DIAL-IN #: 877-291-4570 (USA & Canada) DIAL-IN# 647-788-4919 (International)AN ACCOMPANYING PRESENTATION WILL ALSO BE AVAILABLE. DETAILS FOR ACCESS WILL BE INCLUDED IN THE FOURTH QUARTER PRESS RELEASE. CONFERENCE CALL WILL BE AVAILABLE BY WEBCAST Click on following link to pre-register https://onlinexperiences.com/Launch/QReg/ShowUUID=41FABFC7-E33A-4869-A1A6-7C514464F669 DIGITIZED REPLAY DIAL-IN #: 800-585-8367 (USA & Canada) DIAL-IN #: 416-621-4642 (International) ACCESS CODE: 1166606 SCHEDULE: March 15 @ 1h00 p.m. ending April 15 @ 11:59 p.m. E.T.FOURTH QUARTER RESULTS WILL BE PUBLISHED BEFORE MARKET OPENS, MARCH 15 THROUGH...

Alkame Holdings Begins Production of Maury Island Farm Jams and Quinn’s Pepper Jellies

Written by Customer Service on March 14, 2022. Posted in Public Companies.

LAS VEGAS, March 14, 2022 (GLOBE NEWSWIRE) — Alkame Holdings, Inc. (OTC PINK: ALKM) is pleased to announce that its wholly owned subsidiary, West Coast Copacker is beginning production of Maury Island Farms Jams and Quinn’s Pepper Jellies. These 2 long standing Pacific Northwest brands were acquired by ALKM earlier this year and the company has already made huge strides in transitioning the ownership and integration of both new and existing sales and distribution partnerships and platforms as well as beginning its entry into the direct-to-consumer sector. “We are very excited to finally begin the physical production of Quinn’s and Maury Island,” stated Alkame CEO Robert Eakle. “Our entry into these stable business sectors with two long established clean label premium local brands will provide steady growth for years to come.” About...

DATA443 DEPLOYS MARKET LEADING DATA PRODUCT FOR FLAGSHIP GLOBAL BANK IN UAE – EMIRATES NBD

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Data Product Selected and Deployed After Rigorous Product Selection as Company Pursues Market Uplist RESEARCH TRIANGLE PARK, NC, March 14, 2022 (GLOBE NEWSWIRE) — Data443 Risk Mitigation, Inc. (“Data443” or the “Company”) (OTCPK: ATDSD, OTCPK: ATDS), the leading data security and privacy software company for ALL THINGS DATA SECURITY™, is pleased to announce its partnership with Emirates NBD Group, a leading banking group in the MENAT (Middle East, North Africa and Turkey) region for the deployment of its market-leading data product. The multi-year subscription-based agreement spans the technology landscape of the bank and is part of the banks’ strategic plan to support its ‘cloud first’ approach to rapidly migrate its data and user base to the cloud. Miguel Rio-Tinto, Group Chief Information Officer, Emirates NBD, commented, “As...

Form 8.3 – Pearson plc

Written by Customer Service on March 14, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Jupiter Fund Management Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Pearson plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date dealing undertaken: For an opening position disclosure,...

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder Covid-19 Programs Include Upcoming Phase 2 Trial in Long Covid, Results of First-in-Human T Cell Immunity Skin Test and New Versions of Our Live Virus Covid-19 Vaccine That Express Spike Proteins From the Omicron and BA.2 Variants Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for Future Pandemic Responses Orphan-Drug Designation Granted for TNX-2900 (Intranasal Potentiated Oxytocin) for Prader-Willi Syndrome Cash and Cash Equivalents Totaled Approximately $179 Million at December 31, 2021 CHATHAM, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP)...

AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021 – – Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, March 14, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance...

Assure Holdings Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Full Year 2021 Managed Case Volume Increased 76% to 17,436 Substantially Improved Adjusted EBITDA DENVER, March 14, 2022 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, reported financial results for the fourth quarter and full year ended December 31, 2021.Key Financial Metrics (in thousands of Dollars) 4Q’21 4Q’20 Full Year2021 Full Year2020Revenue $ 9,659 $ 5,964 $ 29,192 $ 3,524 Gross Profit 5,297 3,114 14,874 (4,388 )Total operating expenses 5,013 4,392 17,001 11,815 Adjusted EBITDA 1,400 752 1,144 (14,397 )*- See Explanation of Non-GAAP Financial Measures below for an explanation of Adjusted EBITDA and a reconciliation to GAAP financial measuresKey...

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

Written by Customer Service on March 14, 2022. Posted in Public Companies.

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune’s artificial antigen presenting cells’ (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation. “NexImmune is excited to have...

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022 Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human investigator-initiated trial (IIT) in China in B-cell malignancies with early data to be presented at AACR 2022 Well-funded with cash runway into 2024 Management to host conference call at 8:00 a.m. ET todayPALO ALTO, Calif. and SUZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided...

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

Written by Customer Service on March 14, 2022. Posted in Public Companies.

First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam) Baseline characteristics indicate all nine infants and toddlers enrolled in RESPOND had suboptimal clinical status in ≥2 areas after receiving Zolgensma® (onasemnogene abeparvovec); there were no new safety findings with subsequent SPINRAZA® (nusinersen) treatment New NURTURE results continue to show the potential long-term benefit of early treatment before SMA symptom onset, with 92 percent of participants now able to walk alone, most in age-appropriate timelinesCAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy...

Day: March 14, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice